FDA Approves Tecentriq for Early NSC Lung Cancer

The FDA has approved atezolizumab (brand name Tecentriq, Genetech) as adjuvant treatment following surgery and platinum-based chemotherapy for adults with Stage II-IIIA non-small cell lung cancer.